The degree and extent of changes in cerebral blood¯ow (CBF) caused by pain depends on the characteristics of the stimulus 1±3 and its site of application. 3 To investigate the effects of surgical pain on cerebral haemodynamics we used mechanical pressure, which closely mimics surgical pain, in volunteers. We used transcranial Doppler sonography (TCD) to assess pain-induced changes in cerebral haemodynamics.
Analgesics such as remifentanil and nitrous oxide reduce the sensation of pain, so effects on CBF are likely. We measured CBF velocity in the middle cerebral artery (CBFV MCA ) when remifentanil or nitrous oxide were given to volunteers experiencing pain caused by increasing mechanical pressure.
Methods
After approval by the local university ethics committee and with written informed consent, 10 right-handed, nonsmoking male volunteers (ASA physical status I) with no history of any drug or alcohol abuse took part in this study. The volunteers were randomly assigned by computer (SPSS random function, Version 11.0, SPSS inc., Chicago, IL, USA) to receive remifentanil or nitrous oxide on one day, with the other drug being investigated the next day. Investigation of the effect of the analgesic was preceded by control measurements of CBFV MCA , with and without pain caused by mechanical pressure.
A continuous infusion of remifentanil was given at three doses: 0.025, 0.05 and 0.1 mg kg ±1 min ±1 , in ascending order. Each continuous infusion was preceded by a loading dose (e.g. 25% increased infusion rate for 5 min). After an additional 15 min of steady-state infusion of remifentanil, CBFV MCA was measured with and without pain. Further control measurements were made 20 min after stopping the remifentanil infusion.
The volunteers inhaled three different mixtures of nitrous oxide in oxygen [20%, 35%, 50% end-tidal concentration (FE¢ N 2 O )] in ascending order. A minimum of 20 min was allowed for stabilization of the end-tidal concentration before measuring CBFV MCA with and without pain. Further control measurements were made 20 min after stopping nitrous oxide inhalation.
Pain was caused with a locally constructed pneumatic piston (contact area 1.2 cm 2 ), which was ®xed to the anterior margin of the left tibia, 5 cm above the ankle. The pressure in the piston was increased by 20 kPa (or 2.4 N) every 5 s. The volunteers were instructed to switch off the device when pain became intolerable. To avoid tissue damage, the pressure was stopped after 90 s. The supply pressure was computer controlled using locally developed software.
CBFV MCA was measured by TCD using a ®xed 2-MHzpulsed TCD device (Multi-Dop-L, DWL, Sipplingen, Germany). The Doppler probe was placed on the right side of the head above the zygomatic arch between the lateral margin of the orbit and the ear, and directed toward the M1 segment of the middle cerebral artery at a depth of 50±55 mm, depending on the quality and stability of the signal.
Only one side was measured to avoid any variation related to changes in the site of recording. All TCD measurements were made by the same investigator.
During the experiment, the volunteer wore a closely ®tting facemask and breathed at a constant FE¢ CO 2 (e.g. 40 mm Hg). This value was sustained by additional verbal command when necessary. To minimize the risk of acid aspiration, volunteers fasted for 6 h before the experiment. To assess sedative side-effects of the two drugs, the bispectral index (BIS) (BISÔ Model A-2000Ô (v 3.4); Aspect Medical Systems International BV, Leiden, The Netherlands) was measured.
The fraction of inspired and expired oxygen, end-tidal carbon dioxide concentration (FE¢ CO 2 ), respiratory frequency, non-invasive mean arterial pressure and pulse oximeter haemoglobin saturation (Sp O 2 ) were monitored 
Statistical analysis
Data are presented as mean (SE). Data were tested for normal distribution using the Kolmogorov±Smirnov test. Pairwise comparison of CBFV MCA values at baseline and with the various doses of both agents with and without pain was performed using ANOVA for repeated measurements. Pain-induced changes in CBFV MCA s ±1 (D-CBFV MCA / duration of pain application in s) were calculated as follows:
CBFV MCA drug and pain cm s À1 À CBFV MCA drug only cm s À1 duration of pain application s P<0.05 was considered statistically signi®cant.
Results
We studied 10 volunteers, mean age 27 (range 18±35) yr; mean weight, 79 (SD 11) kg; mean height: 182 (6) cm without complications. Haemodynamic values (heart rate, mean arterial pressure), respiratory parameters (Sp O 2 , FE¢ CO 2 , frequency) and BIS values were not affected by either nitrous oxide or remifentanil. Control measurements of CBFV MCA before and after administration of nitrous oxide or remifentanil were comparable (Fig. 1) . Nitrous oxide increased CBFV MCA with 50% FE¢ N 2 O , whereas remifentanil did not in¯uence CBFV MCA (Fig. 1) .
Pain increased D-CBFV MCA s ±1 at control (Figs 2 and 3) . The increase in D-CBFV MCA s ±1 was attenuated during administration of nitrous oxide (35% and 50% FE¢ N 2 O ; Fig. 2 ) and all concentrations of remifentanil (Fig. 3) . 
Discussion
In our volunteers the increases in CBF caused by pain were reduced by both remifentanil and nitrous oxide.
With TCD, blood¯ow velocities can be measured noninvasively and continuously through the intact skull. 4 Assuming that the diameter of the large cerebral arteries in the circle of Willis (measuring points) does not change greatly, velocity changes will be related to changes in CBF. 5 Hence changes in the calibre of the small resistance vessels caused by metabolic changes (e.g. during periods of pain) should cause corresponding velocity changes indicative of changes in CBF.
In a previous TCD study, 6 thermal pain (e.g. cold pressor test) decreased CBFV MCA . In a study using positron emission tomography (PET), chemical pain caused by capsaicin decreased global CBF. 7 With regard to regional CBF, however, various PET studies found that pain could increase or decrease regional CBF. In fact, variations in both the intensity and the distribution of regional CBF changes have been observed depending on the physical characteristics of the stimulus (e.g. heat vs cold; 1 2 chemical vs electrical or laser 3 ) or its site of application (skin vs subcutaneous or muscles). In the present study, pain caused by pressure combined the features of cutaneous, subcutaneous and muscular pain. Surgical pain possesses a combination of these qualities. The intensity of surgical pain depends on the site and stage of the operation. To mimic an episode of increasing pain intensity, we gradually increased pain intensity to the point of intolerance. To account for changes in pain threshold at baseline and during remifentanil or nitrous oxide administration, the duration of pain application was taken into account when we calculated D-CBFV MCA s ±1 . When attention is directed towards or away from a painful stimulus, this can affect electrocortically evoked potentials 8 9 as well as pain-induced changes in regional CBF. 10 In the present study, attention was directed towards the increasing pain, and the volunteers had to actively discontinue this stimulus when the pain became intolerable. We can assume that mechanical pain increased D-CBFV MCA s ±1 not only by its speci®c physical characteristics but also because of the high level of attention present. The importance of such attention is clear in the effects of non-painful cognitive tasks, which increase CBFV MCA in volunteers. 11 In this study, both nitrous oxide and remifentanil reduced the pain-induced increase in D-CBFV MCA s ±1 . One possible explanation for this is that the state of attention of the subjects could have been altered by the agents. BIS monitoring and clinical impression, however, gave no indication of changes in vigilance and or attention in any volunteers at any time during the experiment. Thus, decreased pain perception with no obvious change in attention probably explains the decrease in D-CBFV MCA s ±1 during administration of nitrous oxide or remifentanil. Alternatively, the observed changes in D-CBFV MCA s ±1 could merely re¯ect pain-induced changes in systemic haemodynamics. In the present study, nitrous oxide and remifentanil did not cause any changes in arterial pressure or heart rate. Reliable non-invasive measurements during the relatively short periods of increasing pain (<90 s) were not possible. Cerebral autoregulation is maintained with these doses of remifentanil. 12 Therefore, changes in arterial pressure (e.g. during increasing pain) are unlikely to have caused the observed changes in CBFV. However, nitrous oxide at 50% FE¢ N 2 O does affect autoregulation, 13 so the observed changes in D-CBFV MCA s ±1 could have been caused by circulatory effects.
The effect of the agents on CBFV MCA in the absence of pain is of interest. In the absence of pain, remifentanil had no effect on CBFV MCA . Similarly, in a previous study, Paris and colleagues 14 showed that an even higher dose (e.g. 2 mg kg ±1 ) of remifentanil did not affect CBFV MCA in anaesthetized patients. In spontaneously breathing volunteers, however, remifentanil (0.1 mg kg ±1 min ±1 ) increased regional CBF, especially at brain sites rich in opioid receptors, at a dose comparable to that used in the present study. 15 In the absence of pain, nitrous oxide increased CBFV MCA only at the highest dose used (50% FE¢ N 2 O ). Nitrous oxide increases CBFV MCA when given to normocapnic volunteers. 16 Hyperventilation counteracted this nitrous oxideinduced increase in CBFV MCA . 16 17 Thus, pain-induced hyperventilation could have reduced CBFV MCA when nitrous oxide was given during increasing pain. In the present study, however, normocapnia was meticulously maintained using FE¢ CO 2 , which correlates well with Pa CO 2 .
18±20 In some cases, the changes in ventilation caused by pain were too short (e.g. duration of <60 s) to signi®cantly alter Pa CO 2 . Therefore, it is unlikely that changes in Pa CO 2 were responsible for the changes observed in D-CBFV MCA s ±1 , whether during administration of nitrous oxide or remifentanil alone or during the painful stimulus and administration of analgesic. This is all the more important because cerebrovascular reactivity to carbon dioxide remains intact during administration of remifentanil 21 and nitrous oxide. 22 In conclusion, we found that mechanical pain increases CBFV MCA in human volunteers. These pain-induced changes in D-CBFV MCA s ±1 were attenuated during inhalation of nitrous oxide or adminstration of remifentanil.
